Zubsolv buprenorphine/naloxone: Phase III data

The double-blind, crossover, U.S. Phase III ISTART trial (OX219-006) in 758 patients with opioid dependence showed that Zubsolv met the co-primary endpoint of non-inferiority to Suboxone buprenorphin...